Comparison of the Predictive and Prognostic Capacities of Neutrophil, Lymphocyte and Platelet Counts and Tumor-infiltrating Lymphocytes in Triple-negative Breast Cancer: Preliminary Results of the PERCEPTION Study

被引:0
作者
Giro, Alexia [1 ,2 ,3 ]
Passildas-Jahanmohan, Judith [1 ,2 ,3 ]
Kossai, Myriam [2 ,4 ]
Bidet, Yannick [2 ,5 ]
Molnar, Ioana [1 ,2 ,3 ]
Bernadach, Maureen [1 ,2 ]
Penault-Llorca, Frederique [2 ,4 ]
Abrial, Catherine [1 ,2 ,3 ]
Durando, Xavier [1 ,2 ,3 ]
Radosevic-Robin, Nina [1 ,2 ,4 ,6 ]
机构
[1] Ctr Jean Perrin, Clin Res & Innovat Dept, Clermont Ferrand, France
[2] Univ Clermont Auvergne, INSERM, IMOST, U1240, Clermont Ferrand, France
[3] Clin Invest Ctr, UMR 501, Clermont Ferrand, France
[4] Ctr Jean Perrin, Dept Pathol, F-63011 Clermont Ferrand, France
[5] Ctr Jean Perrin, Mol Oncol Lab, Clermont Ferrand, France
[6] Ctr Jean Perrin, Dept Pathol, Platform Adv & Novel Tissue Anal TANYA, Clermont Ferrand, France
关键词
Triple-negative breast cancer; biomarker; tumor-infiltrating lymphocytes; neutrophil-to-lymphocyte ratio; CD8/FoxP3; ratio; NEOADJUVANT CHEMOTHERAPY; SURVIVAL; RATIO; RESPONSES; FOXP3; TILS; CD8;
D O I
10.21873/anticanres.17323
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Triple-negative breast cancer (TNBC) is the most heterogeneous breast cancer subtype, posing numerous challenges in clinical decision-making. Biomarkers are essential to personalize management of TNBC patients. While tumor infiltrating lymphocytes (TILs) are validated prognostic biomarkers, the requirement for tumor biopsy limits their routine use. Therefore, more accessible and reliable quantitative biomarkers are needed. Given the significant role of systemic inflammatory response in tumor onset and progression, assessing inflammatory cells via liquid biopsies emerges as a promising alternative. Patients and Methods: The PERCEPTION study, conducted at Centre Jean Perrin in France, aims to determine the correlation between TILs and peripheral blood components at diagnosis. An interim analysis was conducted after enrolling 50% of the estimated population, to evaluate study feasibility and preliminary correlations between blood cell counts and TILs. Results: Sixtyone patients were enrolled over 4.5 years, demonstrating a good inclusion rate with minimal missing data. Preliminary results for 36 analyzable patients showed no correlation between the neutrophil-to-lymphocyte ratio (NLR) and TILs (rs=-0.19, 95%CI=-0.49-0.16, p=0.3). However, a moderate, positive, statistically significant correlation was found between NLR and the CD8/FoxP3 TILs ratio (rs=0.36, 95%CI=0.030.64, p=0.043). The probabilistic index of 0.7 (p=0.06) between NLR-high and NLR-low groups for this ratio supports the correlation. Conclusion: The interim analysis of the PERCEPTION study confirms the feasibility of correlating blood cell counts with TILs in TNBC. Although no significant correlation was observed between NLR and TILs, the moderate positive correlation between the CD8/FoxP3 ratio and TILs suggests a potential link between systemic inflammation and local immune response. These findings underscore the potential of blood-based markers as non-invasive surrogates for TILs, encouraging further research to enhance prognosis and guide treatment strategies in TNBC.
引用
收藏
页码:4983 / 4994
页数:12
相关论文
共 64 条
  • [1] Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer
    Asano, Y.
    Kashiwagi, S.
    Goto, W.
    Kurata, K.
    Noda, S.
    Takashima, T.
    Onoda, N.
    Tanaka, S.
    Ohsawa, M.
    Hirakawa, K.
    [J]. BRITISH JOURNAL OF SURGERY, 2016, 103 (07) : 845 - 854
  • [2] Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ
    Beguinot, Marie
    Dauplat, Marie-Melanie
    Kwiatkowski, Fabrice
    Lebouedec, Guillaume
    Tixier, Lucie
    Pomel, Christophe
    Penault-Llorca, Frederique
    Radosevic-Robin, Nina
    [J]. BMC CANCER, 2018, 18
  • [3] Pathology of triple negative breast cancer
    Borri, Filippo
    Granaglia, Annarita
    [J]. SEMINARS IN CANCER BIOLOGY, 2021, 72 : 136 - 145
  • [4] Bozkurt O, 2015, J BUON, V20, P1432
  • [5] Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy
    Ceze, N.
    Thibault, G.
    Goujon, G.
    Viguier, J.
    Watier, H.
    Dorval, E.
    Lecomte, T.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1305 - 1313
  • [6] Common Terminology Criteria for Adverse Events (CTCAE), About us
  • [7] Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review
    Corbeau, Ileana
    Jacot, William
    Guiu, Severine
    [J]. CANCERS, 2020, 12 (04)
  • [8] Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies
    Cupp, Meghan A.
    Cariolou, Margarita
    Tzoulaki, Ioanna
    Aune, Dagfinn
    Evangelou, Evangelos
    Berlanga-Taylor, Antonio J.
    [J]. BMC MEDICINE, 2020, 18 (01)
  • [9] Triple negative breast cancer: A thorough review of biomarkers
    da Silva, Jesse Lopes
    Cardoso Nunes, Natalia Cristina
    Izetti, Patricia
    de Mesquita, Guilherme Gomes
    de Melo, Andreia Cristina
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 145
  • [10] Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
    Denkert, Carsten
    von Minckwitz, Gunter
    Darb-Esfahani, Silvia
    Lederer, Bianca
    Heppner, Barbara I.
    Weber, Karsten E.
    Budczies, Jan
    Huober, Jens
    Klauschen, Frederick
    Furlanetto, Jenny
    Schmitt, Wolfgang D.
    Blohmer, Jens-Uwe
    Karn, Thomas
    Pfitzner, Berit M.
    Kuemmel, Sherko
    Engels, Knut
    Schneeweiss, Andreas
    Hartmann, Arndt
    Noske, Aurelia
    Fasching, Peter A.
    Jackisch, Christian
    van Mackelenbergh, Marion
    Sinn, Peter
    Schem, Christian
    Hanusch, Claus
    Untch, Michael
    Loibl, Sibylle
    [J]. LANCET ONCOLOGY, 2018, 19 (01) : 40 - 50